SK Biopharma and Eurofarma launch AI epilepsy venture Mentis Care

South Korea’s SK Biopharmaceuticals (KRX: 326030) has partnered with Brazil’s Eurofarma to launch Mentis Care, a Toronto-based joint venture developing an AI-powered epilepsy management platform. The venture, announced October 20, marks SK Biopharmaceuticals’ first formal expansion into digital healthcare beyond its established drug portfolio.

Located within the MaRS Discovery District, one of North America’s largest life sciences innovation hubs, Mentis Care will integrate SK Biopharmaceuticals’ expertise in electroencephalography and wearable seizure-monitoring technology with Eurofarma’s digital and commercial capabilities. The platform aims to combine real-time seizure detection and predictive algorithms with clinical decision-support tools for individualized care.

Eurofarma, which operates across 24 countries, will oversee the joint venture’s business strategy and AI data learning. The companies have worked together since 2022 on commercializing SK’s anti-seizure medicine cenobamate (XCOPRI) in Latin America. Mentis Care extends this partnership into digital health, reflecting both firms’ push toward integrated therapeutic ecosystems.